2023
Value-driven colorectal cancer survivorship through partnership with primary care.
Chan G, Ho C, Lin Z, Wu J, Chieng J, Lieske B, Yong W, Sundar R, Tan H, Ho J, Choo J, Walsh R, Cheong W, Tan K, Chee C, Liu X, Lim F, Goh S, Chee C. Value-driven colorectal cancer survivorship through partnership with primary care. Journal Of Clinical Oncology 2023, 41: 6649-6649. DOI: 10.1200/jco.2023.41.16_suppl.6649.Peer-Reviewed Original ResearchPrimary care providersSurvivorship careHealthcare resourcesPrimary careSpecialist visitsColorectal cancerStage distribution of cancersColorectal cancer survivorshipColorectal cancer survivorsSurvivorship care plansUtilization of healthcare resourcesCancer CenterFollow-up careDistribution of cancerNational University Cancer InstituteAcademic cancer centerCancer recurrenceCRC survivorsCancer survivorshipCare planningCare providersHealthcare utilizationPreventive healthHealthcare expendituresTertiary care
2019
Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
Molassiotis A, Cheng H, Leung K, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Lopez V. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain And Behavior 2019, 9: e01312. PMID: 31063261, PMCID: PMC6576180, DOI: 10.1002/brb3.1312.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyDevelopment of chemotherapy-induced peripheral neuropathyHistory of neuropathyRisk factorsPeripheral neuropathyPlatinum-based chemotherapySymptom burdenPotential risk factorsVegetable/fruit intakeWHO criteriaChemotherapy cyclesAlcohol intakeSmoking historyUnivariate analysisChemotherapyMultivariate regression modelMedical historyTreatment characteristicsNeurotoxic chemotherapyKey risk factorsNeuropathyCancer CenterSide effectsQuality of lifeTreatment decisions